Yuichi Sugiyama
Overview
Explore the profile of Yuichi Sugiyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
422
Citations
9682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoshikado T, Aoki Y, Nakamura R, Shida S, Sugiyama Y, Chiba K
CPT Pharmacometrics Syst Pharmacol
. 2025 Feb;
PMID: 39920884
Grazoprevir (GZR), a direct-acting agent for hepatitis C virus, is recognized as a substrate for organic anion transporting polypeptide 1B (OATP1B), cytochrome P450 3A (CYP3A), and P-glycoprotein (P-gp). The objective...
2.
Tsuchitani T, Kato M, Tomaru A, Aoki Y, Sugiyama Y
Clin Transl Sci
. 2024 Nov;
17(12):e70034.
PMID: 39600105
In drug discovery and development, estimating therapeutic and subtherapeutic doses is crucial for designing early-phase clinical trials, particularly first-in-human (FIH) studies. While increasing the in vitro pharmacological potency (lowering K)...
3.
Koishikawa T, Fujiwara K, Taskar K, Zamek-Gliszczynski M, Yoshida K, Chu X, et al.
Clin Pharmacol Ther
. 2024 Nov;
117(2):523-533.
PMID: 39497599
This study was designed to assess the quantitative performance of endogenous drug-drug interaction (DDI) biomarkers (N1-methylnicotinamide (1-NMN), N1-methyladenosine (mA), and creatinine) for the organic cation transporters, OCT2 and MATE1/2K in...
4.
Nakamura R, Yoshikado T, Aoki Y, Sugiyama Y, Chiba K
Clin Transl Sci
. 2024 Oct;
17(10):e70047.
PMID: 39435882
The dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (LNG) exhibits target-mediated drug disposition (TMDD) in clinical settings, characterized by saturable binding to plasma soluble DPP-4 (sDPP-4) and tissue transmembrane DPP-4 (tDPP-4). Previous...
5.
Aoki Y, Rowland M, Sugiyama Y
Front Pharmacol
. 2024 Aug;
15:1366160.
PMID: 39119606
Intra-Target Microdosing (ITM), integral to Phase 0 clinical studies, offers a novel approach in drug development, effectively bridging the gap between preclinical and clinical phases. This methodology is especially relevant...
6.
Weiss H, Sugiyama Y, van Duijn E
Front Pharmacol
. 2024 Jul;
15:1455643.
PMID: 39081956
No abstract available.
7.
Tsuchitani T, Tomaru A, Aoki Y, Ishiguro N, Tsuda Y, Sugiyama Y
CPT Pharmacometrics Syst Pharmacol
. 2024 May;
13(7):1224-1237.
PMID: 38745377
Telmisartan, a selective inhibitor of angiotensin II receptor type 1 (AT1), demonstrates nonlinear pharmacokinetics (PK) when orally administered in ascending doses to healthy volunteers, but the underlying mechanisms remain unclear....
8.
A case of perforation of the prostatic abscess into the rectum resulting in a rectoprostatic fistula
Sugiyama Y, Fujikawa A, Yokokawa S
IJU Case Rep
. 2023 Nov;
6(6):433-435.
PMID: 37928312
Introduction: A rectoprostatic fistula complicating a prostatic abscess is extremely rare, and there are many uncertainties regarding its treatment and prognosis. Case Presentation: We present the case of a 68-year-old...
9.
Aoki Y, Sugiyama Y
CPT Pharmacometrics Syst Pharmacol
. 2023 Oct;
13(1):54-67.
PMID: 37853850
Physiologically-based pharmacokinetic (PBPK) models can be challenging to work with because they can have too many parameters to identify from observable data. The profile likelihood method can help solve this...
10.
Nakayama S, Toshimoto K, Yamazaki S, Snoeys J, Sugiyama Y
CPT Pharmacometrics Syst Pharmacol
. 2023 Sep;
12(10):1461-1472.
PMID: 37667529
The orally available anti-hepatitis C virus (HCV) drug simeprevir exhibits nonlinear pharmacokinetics at the clinical doses due to saturation of cytochrome P450 (CYP) 3A4 metabolism and organic anion transporting peptide...